[HTML][HTML] Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
[PDF][PDF] Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Féasson, M Hanna… - researchgate.net
Serum concentrations of myostatin (MSTN or GDF8), follistatin (FSTN), GDF11 and ACTIVIN
A were determined in patients affected by several neuromuscular diseases with various …
A were determined in patients affected by several neuromuscular diseases with various …
[引用][C] Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Feasson, M Hanna… - 2017 - agris.fao.org
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of
anti-myostatin therapeutic approaches Food and Agriculture Organization of the United Nations …
anti-myostatin therapeutic approaches Food and Agriculture Organization of the United Nations …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Féasson… - Nature …, 2017 - hal.science
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé… - Nature …, 2017 - econpapers.repec.org
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Féasson… - Nature …, 2017 - discovery.ucl.ac.uk
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé… - Nature …, 2017 - ui.adsabs.harvard.edu
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
[HTML][HTML] Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Féasson… - Nature …, 2017 - ncbi.nlm.nih.gov
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé, L Féasson… - Nature …, 2017 - ideas.repec.org
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
V Mariot, R Joubert, C Hourdé… - Nature …, 2017 - pubmed.ncbi.nlm.nih.gov
Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …